1-Star Price
INVESTOR
5-Star Price
INVESTOR
Economic Moat
INVESTOR
Capital Allocation
INVESTOR
We believe Icon possesses all the necessary elements to win share in the late-stage contract research organization market: global capabilities, full-service offerings, extensive regulatory and clinical expertise, investment in innovation and technology, and operational excellence. Icon is one of a handful of CROs with the global infrastructure to carry out late-stage, multinational trials and hone international regulatory expertise.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Morningstar analysts hand-select direct competitors or comparable companies to provide context on the strength and durability of ICLR’s competitive advantage.
Icon PLC
XNAS: ICLR
| IQVIA Holdings Inc
XNYS: IQV
| Syneos Health Inc Class A
XNAS: SYNH
| Medpace Holdings Inc
XNAS: MEDP
| |
Price
| 246.70 | 200.98 | 42.97 | 242.15 |
Currency
| USD | USD | USD | USD |
Change
| −$3.71 (1.48%) | −$1.41 (0.70%) | +$0.19 (0.44%) | −$2.55 (1.04%) |
Market Cap
| 20.27 Bil | 36.80 Bil | 4.46 Bil | 7.40 Bil |
Industry
| Diagnostics & Research | Diagnostics & Research | Diagnostics & Research | Diagnostics & Research |
Sector
|
Healthcare
|
Healthcare
|
Healthcare
|
Healthcare
|
* Trading data in this section is delayed by at least 15 minutes.
No. ICLR does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.
Learn more about dividend yield.
ICLR’s market cap is 20.27 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.
It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the
largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.
Learn more about market capitalization.
ICLR’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns.
Style is calculated by combining value and growth scores, which are first individually calculated.
High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.
Learn more about style.
ICLR’s price/sales is 2.58.
Price/sales represents the amount an investor is willing to pay for a dollar generated from
a particular company’s sales or revenues.
ICLR’s price/forward earnings is 39.92.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates.
The lower the Forward P/E, the cheaper the stock.
ICLR’s price/book is 2.30.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets,
based on historical, rather than current, valuations. Historical valuations generally do not reflect
a company’s current market value. Value investors frequently look for companies that have low price/book ratios.
See ICLR’s valuation ratios compared to the Market Index.
ICLR’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.
Compare ICLR’s historical performance against its industry peers and the overall market.
